E European Society of Intensive Care Medicine (ESICM) on the ABC-T Task Force. DF represented the European Society of Anaesthesiology (ESA) on the ABC-T Task Force. RK represented the European Society of Trauma and Emergency Surgery (ESTES) on the ABC-T Task Force. YO represented the European Society of Intensive Care Medicine (ESICM) on the ABC-T Task Force. LR represented the European Society for Emergency Medicine (EuSEM) on the ABC-T Task Force. AS represented the European Shock Society (ESS) on the ABC-T Task Force. RR serves as chair of the ABC-T European Medical Education Initiative. Competing interests BB has received honoraria for consulting from Novo Nordisk, CSL Behring and Sangart. VC has received honoraria for consulting or lecturing from B. Braun, Fresenius, Novo Nordisk and MSD. He PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/12027669 has received research grant funding and institutional support from Charles University in Prague (Czech Republic). TJC has received research grant funding from the National Institute of Health Research and the College of Emergency Medicine. He has received institutional support from the University of Leicester. JD has received institutional support from Assistance Publique Hopitaux de Paris and Paris-Sud University. EFM has received honoraria for consulting from Sangart and CSL Behring. He is member of Medical Advisory Board of Pulsion BJH. DF has received honoraria for consulting or lecturing from Abbott, Sanofi Aventis, Servier and ViforPharma, institutional support from Abbott, Edwards (E)-1,2-Di(pyridin-4-yl)ethene Lifescience, Infomed Fluids, Medtronic, Nycomed, Pfizer, Servier, Siramed and ViforPharma and travel grants from B. Braun, Fresenius Kabi and GlaxoSmithKline. BJH has received no personal pecunary benefit PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/9871638 from pharmaceutical companies, but donated all honoraria from lecturing to charity. She was a joint investigator on a research study funded by Sanofi. BJH does not sit on advisory boards to pharmaceutical companies, but sits on an advisory board for Haemonetics. RK has 2-Bromo-1,3-difluoro-4-nitrobenzene received honoraria for consulting and lecturing from Eli Lilly and Amgen. MM has received honoraria for consulting or lecturing from Novo Nordisk, CSL Behring and Biotest. He has received research grant funding and institutional support from the Private University Witten-Herdecke (Germany). He has served as a Medical Advisory Board member for CSL Behring. GN has received honoraria for consulting and lecturing from CSL Behring and honoraria for 4-Dichloro-6-methylpyridine n-(2-Hydroxypropyl)acetamide 4-Chloro-2-methylquinoline 2-Ethynylthiophene 4-Bromo-3-methoxybenzaldehyde (R)-1-N-Boc-piperazine-3-carboxylic acid methyl ester 1-(4-Fluoro-2-methylphenyl)ethan-1-one 2-Bromo-6-methyl-4-(trifluoromethyl)pyridine 7-​Hexadecanone Furo[3 lecturing from Fresenius Kabi. He has received a research grant from Sangart and a research grant (institutional research) from Novo Nordisk. EN has received honoraria for consulting or lecturing from BIOMET, Pfizer, QRx Pharma, MSD, Gr enthal and Therabel. He has received research grant funding from BMBF, DFG, Else-Kr er Foundation, different societies and has received institutional support from KCI, Pfizer, Mundipharma, BIOMET and Janssen. I YO has received honoraria for consulting or lecturing from LFB and CSL Behring. LR been involved in educational courses on bleeding control supported by Baxter. RR has received honoraria for consulting or lecturing from CSL Behring, Novo Nordisk, Bayer Healthcare and Air Liquide. He has received research grant funding from CSL Behring, Boehringer Ingelheim, Air Liquide, Biotest, Nycomed and Novo Nordisk. AS has no competing interests to declare. DRS’s academic department has received grant support from the Swiss National Science Foundation, Berne, Switzerland (grant numbers: 33CM30_124117 and 406440-131268), the Swis.